Status:

RECRUITING

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

Lead Sponsor:

CooperVision, Inc.

Conditions:

Myopia

Eligibility:

All Genders

8-12 years

Phase:

NA

Brief Summary

The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year ...

Detailed Description

This study is a multicenter, parallel-group, controlled, double-masked (subject and investigator), randomized clinical trial with a total duration of four years. Part 1 of this study will study the e...

Eligibility Criteria

Inclusion

  • Informed Consent and Assent have been completed
  • Be between 8 and 12 years of age inclusive at the time of enrollment.
  • Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.75 D and -4.00 D inclusive (at the corneal plane) in each eye
  • Best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.
  • Anisometropia: ≤ 1.50D SERE.
  • Astigmatism: ≤ 0.75 D
  • Free of ocular disease or abnormalities (including any corneal scar)
  • Currently have good general health.
  • Agree to accept the lens as assigned by the randomization.
  • Be capable of comprehending the nature of the study and be willing and able to adhere to the instructions set forth in this protocol.
  • Ability to comply with study procedures, including high and low (sub-study only) contrast high and low (sub-study only) lighting visual acuity, axial length, and cycloplegic auto-refraction measurements taken for both eyes.
  • Able to maintain the visit schedule.
  • Willingness to participate in the trial for 4 years.
  • Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week.
  • Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.

Exclusion

  • Current or prior use of any pharmaceuticals or other methods for control of myopia, such as bifocals, progressive addition lenses, orthokeratology, atropine, pirenzepine or any other myopia control treatment.
  • Use of any systemic or topical ocular medications or over-the-counter artificial tears which might interfere with contact lens wear, pupil size, accommodation or refractive state, or require the lenses to be removed during the day.
  • Previously worn or currently wears rigid gas permeable contact lenses, including orthokeratology lenses
  • Has any of the following specific contraindications to MiSight 1 Day lenses at Baseline Visit:
  • Acute and subacute inflammation or infection of the anterior chamber of the eye.
  • Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids.
  • Severe insufficiency of lacrimal secretion (dry eyes).
  • Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic.
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.
  • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions.
  • Any active corneal infection (bacterial, fungal, or viral).
  • If eyes are red or irritated.
  • The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so.
  • Has history of:
  • Corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
  • Giant papillary conjunctivitis
  • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses
  • A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.
  • Corneal hypoesthesia (reduced corneal sensitivity)
  • Keratoconus or an irregular cornea.
  • Strabismus or amblyopia.
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.

Key Trial Info

Start Date :

June 25 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2027

Estimated Enrollment :

900 Patients enrolled

Trial Details

Trial ID

NCT05285553

Start Date

June 25 2022

End Date

June 30 2027

Last Update

August 17 2025

Active Locations (30)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (30 locations)

1

University of Alabama School of Optometry

Birmingham, Alabama, United States, 35233

2

Marshall B. Ketchum University Southern California College of Optometry

Fullerton, California, United States, 92831

3

Vision Solutions Optometry Inc

La Mesa, California, United States, 91942

4

Paje Optometric

Santa Ana, California, United States, 92704